# Neoadjuvant BKM120 in High-risk Prostate Cancer

> **NCT01695473** · PHASE2 · TERMINATED · sponsor: **Won Kim** · enrollment: 11 (actual)

## Conditions studied

- High Risk Prostate Cancer

## Interventions

- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01695473
- **Lead sponsor:** Won Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04-23
- **Primary completion:** 2015-02-05
- **Final completion:** 2015-02-05
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2021-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01695473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01695473, "Neoadjuvant BKM120 in High-risk Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01695473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*